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ABSTRACT
The frequency and clinical significance of secondary thrombocytopenia following initial engraftment in
autologous hematopoietic progenitor cell transplantation (HPCT) is unknown. An institutional review board
approved retrospective study of thrombopoiesis was performed in 359 patients transplanted with autologous
blood (97%) or marrow (3%) who achieved platelet engraftment to >50,000/L. Idiopathic secondary post-
transplant thrombocytopenia (ISPT) was defined as >50% decline in blood platelets to <100,000/L in the
absence of relapse or sepsis. ISPT occurred at a median of day 35 posttransplant in 17% of patients. Patients
with ISPT had similar initial platelet engraftment (median 17 days) versus non-ISPT patients (18 days; PNS)
and recovered platelet counts (median 123,00 K/L) by day 110 posttransplant. Four factors were indepen-
dently associated with post-transplant death in a multivariate model: disease status at transplant; the number
of prior chemotherapy regimens, failure to achieve a platelet count of >150,000/L posttransplant, and the
occurrence of ISPT. A prognostic score was developed based upon the occurrence of ISPT and posttransplant
platelet counts of <150,000/L. Survival of patients with both factors (n  25) was poor (15% alive at 5 years);
patients with 1 factor (n  145) had 49% 5-year survival; patients with 0 factors (n  189) had 72% 5-year
survival. Patients who failed to achieve a platelet count of >150,000/L received significantly fewer CD34
cells/kg (P < .001), whereas patients with ISPT received fewer CD34CD38 cells/kg (P  .0006). The
kinetics of posttransplant thrombopoiesis is an independent prognostic factor for long-term survival following
autologous HPC. ISPT and lower initial posttransplant platelet counts reflect poor engraftment with long-
term and short-term repopulating CD34 hematopoietic stem cells, respectively, and are associated with an
increased risk of death from disease relapse.
© 2007 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Profound thrombocytopenia occurs in all patients
ollowing myeloablative conditioning and autologous
tem cell rescue, and reﬂects bone marrow aplasia
nduced by high-dose chemotherapy and/or total body
rradiation (TBI). Following autologous hematopoi-
tic progenitor cell transplantation (HPCT), restora-
ion of normal numbers of blood leukocytes and plate-
ets usually follows predictable kinetics within the ﬁrst
onth posttransplant, with increasing numbers of
ranulocytes, platelets, lymphocytes, and ﬁnally eryth- tocytes in the blood. The kinetics of granulocyte re-
overy have been extensively studied in autologous
ransplant recipients leading to identiﬁcation of the
inimum and optimal numbers of CD34 hemato-
oietic progenitors necessary for predictable reestab-
ishment of hematopoiesis [1-3]. Higher numbers of
D34 cells in the graft are associated with more rapid
eutrophil and platelet engrafment [4-6] but not nec-
ssarily better long-term outcomes [7]. The recovery
f a higher number of blood lymphocytes early post-
ransplant has been reported to be associated with
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M. J. Ninan et al.896mproved posttransplant survival, and appears to be
orrelated with transplantation of larger numbers of
ymphocytes in the hematopoietic graft rather than de
ovo lymphopoiesis from lymphocyte progenitors in
he graft [8-12].
In contrast, studies of the kinetics of platelet recov-
ry following HPCT have largely been limited to de-
criptions of the time from transplant to the day of
ndependence from platelet transfusions. Most reports
escribing clinical outcomes following autologous trans-
lantion have compared the median time the blood
latelet counts reached 20,000/L or 50,000/L with-
ut tranfusion support [13]. Although the availability of
yeloid and erythroid growth factors offer safe and
ffective management strategies for mitigating post-
ransplant neutropenia and anemia, respectively, similar
gents are not currently commercially available for the
anagement of posttransplant thrombocytopenia [14].
hus, the platelet count following autologous HPCT
epresents a direct indicator of the hematopoietic activity
f the graft.
A subset of patients who initially recover platelet
ounts after transplantation experience subsequent
econdary posttransplant thrombocytopenia (SPT), or
arying duration, and because of different mechanisms
15]. Sepsis or relapse may result in early SPT; SPT
ccurring 6-12 months posttransplantation has been
anaged with steroids and immune globulin, drugs
hat are used to treat patients with idiopathic throm-
ocytopenia purpura [16,17]. The phenomenon of
diopathic secondary posttransplant thrombocytope-
ia (ISPT), ocurring within the ﬁrst 100 days post-
ransplant, has not been well deﬁned.
To deﬁne the incidence of ISPT, its association
ith pre- and posttransplant variables, the kinetics of
latelet production following autologous transplanta-
ion, and the prognostic signiﬁcance of posttransplant
hrombopoiesis, we undertook a retrospective study of
latelet production in consecutive patients undergo-
ng autologous HPCT at a single institution. We
ypothesized that an idiopathic secondary decline in
lood platelet counts following initial engraftment
ould be associated with transplantation of a hema-
opoietic graft containing fewer numbers of pheno-
ypically undifferentiated CD34 CD38 hematopoi-
tic progenitors [18,19] responsible for long-term
epopulating activity [20].
ETHODS
tudy Design and Definitions
We performed a single institution retrospective co-
ort study on platelet engraftment kinetics and survival
mong consecutive patients undergoing high-dose che-
otherapy and autologous hematopoietic progenitor
ell transplantation. The day of granulocyte engraftment pas deﬁned as the ﬁrst of 3 consecutive days on which
atients had an absolute granulocyte count of at least
00/L. The day of platelet engraftment was deﬁned as
he day platelet counts50,000/L were achieved with-
ut a platelet transfusion in the previous 7 days. Because
here are no existing descriptions of the phenomena of
PT (outside of late posttransplant thrombocytopenia),
PT was deﬁned as a clinically signiﬁcant drop in plate-
et count, of at least a 50% absolute decrease, to a value
100,000/L after initial platelet engraftment achieved.
SPT was deﬁned as SPT within the ﬁrst 100 days
osttransplant in the absence of relapse or sepsis. De-
ographics of the patients, their diagnoses, conditioning
egimens, and characteristics of their grafts were entered
nto a study-speciﬁc, institutional review board (IRB)-
pproved database along with blood counts, transfusions,
nd infections occurring within the ﬁrst 100 days post-
ransplant. Follow-up survival data was available for sur-
iving study subjects for a median of 2 years posttrans-
lant.
tudy Subjects
The study set was derived from 509 consecutive
ancer patients who underwent high-dose chemother-
py and autologous blood (97%) or bone marrow
3%) HPC transplantation between January 1997 and
une 2005. An IRB-approved waiver of consent was
ranted for the conduct of this study. Forty patients
ad insufﬁcient data on posttransplant platelet counts
o assess engraftment, 6 patients died prior to engraft-
ent (1% early death), and 18 patients did not achieve
platelet count of 50,000/L by day 100 (4%
ailure to achieve platelet engraftment). Three hun-
red ﬁfty-nine of the 445 remaining patients (81%)
ad data on the CD34 cell subsets in the autograft
nd constituted the study cohort. Survival was docu-
ented at posttransplant follow-up visits, or by con-
acting the patient or referring oncologist. The date of
eath was conﬁrmed using Social Security Death In-
ex data. The primary cause of death was available for
8% of deceased patients. Treatment regimens were
eﬁned as chemotherapy protocols given as part of a
lanned course of therapy (ie, ABVD); induction che-
otherapy and mobilization with 1 cycle of cyclo-
hosphamide given at the end of 1 course of therapy
ie, VAD) was considered to be a single regimen.
tatistical Methods
All statistical analyses were performed using SPSS
ersion 11.0 (SPSS Inc., Chicago, IL). Comparisons
etween mean values occurred using a Student’s t-test.
omparisons of ordinal characteristics between ISPT
nd controls were performed using a chi-square test.
urvival differences between subgroups were com-
ared using the Kaplan-Meier estimate of survival and
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Posttransplant thrombopoiesis and autologous HPCT 897og rank comparisons, with univariate and multivariate
ox regression models.
ESULTS
osttransplant Platelet Counts Were Biphasic
Inclusion of patients in this retrospective study
as limited to patients who engrafted with a platelet
ount of at least 50,000/L posttransplant; all 359
atients who engrafted with platelets also engrafted
ith granulocytes. Among the 359 study subjects,
3 (20%) met the criteria for SPT within the ﬁrst
00 days posttransplant, achieving a transfusion-
ndependent platelet count of 50,000/L followed
y a 50% decline in their platelet count to a value of
100,000/L. Of these, 11 cases of SPT resulted
rom relapse within the ﬁrst 100 days (6 cases) or
epsis (5 cases), leaving 62 patients (17%) with ISPT,
nd 297 control patients who did not experience
SPT.
Median values for serial blood platelet counts in
he 62 patients with ISPT were compared to 62 pa-
ients selected from the 297 patients of who did not
eet the criteria for ISPT (controls) and are shown in
igure 1A. The subset of controls and the cases had
imilar ages (mean SE) of 44 1.8 years and 48 1.8
ears, respectively, PNS, and a similar distribution of
iagnoses (eg, 58% lymphoma patients versus 61% lym-
homa patients, P  NS). Pretransplant platelet counts
ere similar comparing patients with ISPT to controls,
ith median values (SE) of 184,000/L (12,000/L)
nd 195,000/L (11,000/L), respectively (P  NS).
nitial posttransplant nadir median values (SE) for
latelet counts were 8000/L (600/L) at median of
ay 7 posttransplant in the 62 patients with ISPT
ersus 8000/L (500/L) at median of day 8 post-
ransplant in the group of 297 control patients (P 
S). Platelet engraftment to 50,000/L occurred
lightly earlier among patients in the ISPT group
median  SE of 17  1.6 days) versus control pa-
ients (median 18 0.7 days; PNS). The kinetics of
nitial platelet recovery was similar between the 2
roups, with a rapid rise to maximal median values
SE) of 168,000/L (9000/L) on day 20 (2.3
ays) in ISPT patients versus 191,000/L (6000/
L) on day 23 (1 days) posttransplant in the group
f control patients, P  .01. The initial rise in platelet
ounts was followed by a secondary decline in both
roups. However, the decline in patients with ISPT
as much more profound, falling to a nadir of
5,000/L (4000/L) on day 35 (2) posttransplant
4  1 days after the initial peak (Figures 1A and B).
ost patients with ISPT experienced a subsequent
artial recovery of blood platelet counts to a median
alue of 123,000/L by days 100-110 posttransplant
Figure 1A). TSPT Was More Common in Lymphoma
atients and Patients Treated with
usulfan-Containing Regimens
The demographics of the 62 ISPT patients and
he 297 control patients were similar, with a mean
ge of 50 years for both groups and similar sex
istributions (58% and 56% male, respectively;
igure 1. Comparison of platelet engraftment kinetics in patients
ith ISPT and controls. A, The median values (SE) for platelet
ounts for 62 patients with ISPT (open squares) and 61 patients
ithout ISPT (ﬁlled circles) are shown. After day 15, data are shown
s the median of the highest platelet count recorded for each patient
n a 5-day period (for days 15-50) or a 25-day period (for days
0-100). Signiﬁcant differences between the groups for each time
oint are shown: *P  .05; #P  .001. B, Each line represents an
xponential curve representing the decline from the highest re-
orded value for a postengraftment platelet count to the lowest
osttransplant platelet count in each of the 62 patients with ISPT.
, The median values (SE) for platelet counts for 13 patients with
SPT who received steroids  i.v. immunoglobulin (ﬁlled circles)
nd 49 patients with ISPT who did not receive steroids or immu-
oglobulin (open squares) are shown. After day 15, data are shown
s the median of the highest platelet count recorded for each patient
n a 5-day period (for days 15-50) or a 25-day period (for days
0-100). There were no signiﬁcant differences in the mean platelet
alues between the 2 groups.able 1). Hodgkin’s lymphoma and non-Hodgkin’s
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M. J. Ninan et al.898ymphoma were overrepresented among the group
ith ISPT, as were patients with prior treatment
ith rituximab and busulfan-based conditioning
egimens (Table 1). In contrast, ISPT occurred less
requently in myeloma patients receiving high-
ose melphalan conditioning and in breast cancer
atients. ISPT was not signiﬁcantly associated with
he disease status at the time of transplant, the use
f involved ﬁeld radiotherapy immediately before
he initiation of the conditioning regimen, or the
se of bone marrow versus blood HPC grafts
able 1. Comparison of Clinical Variables between Cases with ISPT
nd Patients Who Did Not Develop ISPT (Controls)
Cases
ISPT
(n  62)
Controls
No ISPT
(n  297) P-value
ge (mean) 53 52 NS
ale sex 36 (58%) 167 (57%) NS
iagnosis .001
HD (n  59) 18 (29%) 41 (14%)
NHL (n  81) 20 (32%) 61 (21%)
MM (n  164) 16 (26%) 148 (50%)
Acute leukemia (n  18) 6 (10%) 12 (4%)
Chronic leukemia (n  1) 1 (2%) 0 (0%)
Solid tumor (n  37) 1 (2%) 36 (12%)
umber of prior regimens NS
None 0 1 (0.3%)
One 25 (40%) 160 (54%)
Two 25 (40%) 106 (46%)
Three 11 (18%) 27 (9%)
Four 1 (2%) 3 (1%)
reconditioning radiation 3 (5%) 21 (7%) NS
reconditioning rituximab 7 (11%) 8 (3%) .002
isease status at transplant NS
CR 28 (45%) 95 (32%)
PR 29 (47%) 176 (59%)
Refractory 5 (8%) 25 (8%)
Untreated 0 1 (0.3%)
onditioning regimen .001
Bu/Cy 5 (8%) 12 (4%)
Bu/Cy/VP 16 40 (65%) 92 (31%)
Melphalan 14 (23%) 144 (48%)
Cy/TBI 2 (3%) 8 (3%)
Cy/VP16/TBI 0 6 (2%)
Cyt/Thio/Carbo 1 (2%) 33 (11%)
Carbo/VP16 0 1 (2%)
PC source NS
BM HPC 0 7 (2%)
Blood HPC 61 (98%) 288 (97%)
BM & PBSC 1 (1%) 2 (1%)
SPT was observed more frequently among patients with a diagno-
sis of lymphoma and acute leukemia, and patients who received
busulfan-based conditioning. ISPT was observed less frequently
in patients with solid tumors and multiple myeloma, and pa-
tients who received melphalan or STAMP V conditioning
regimens.
M indicates bone marrow; PBSC, peripheral blood stem cells;
NHL, non-Hodgkin’s lymphoma; MM, multiple myeloma;
ISPT, idiopathic secondary posttransplant thrombocytopenia;
CR, complete remission; PR, partial remission; TBI, total body
irradiation; HPC, hematopoietic progenitor cell.Table 1). chrombocytopenia in Patients with ISPT Did Not
espond to Steroid or IVIG Therapy
One view of SPT is that it is immune-mediated
17]. The subset of 13 patients with ISPT that
eceived treatment with steroids  IVIG had simi-
ar kinetics of platelet recovery to ISPT patients
ho were not treated (Figure 1C). These 13 treated
SPT patients received an average of 27 days of
rednisone (range: 7-43 days) at an average initial
ose of 75 mg (range: 60-120 mg). The average
otal dose of prednisone over circa 1 month of
herapy was 1295 mg (range: 400-2320 mg). Three
atients received IVG at an average dose of 1500
g/kg delivered over 3-4 days. Bone marrow exam-
nations were performed on a minority of patients in
his study as part of restaging done in some patients
t day 30 posttransplant. Nineteen patients under-
ent bone marrow biopsies prior to day 100 in the
roup of non-ISPT patients; in 4 cases early relapse
as detected; in an additional 15 cases (5% of the
ontrol patients) biopsies performed at a median of
5 days posttransplant revealed no cancer; these
amples were evaluated for cellularity and
egakaryocyte content, and were compared to bone
arrow biopsies from 26 patients with ISPT (42%)
ho underwent biopsies at a median of 35 days
osttransplant. Although the small number of sam-
les limits the statistical power of these analyses,
here was no difference in the cellularity or
egakaryocyte content of the bone marrow in the
roup of 15 non-ISPT patients who underwent
one marrow biopsies compared to the 26 ISPT
atients who underwent bone marrow biopsies (Ta-
le 2). The content of megakaryocytes in the bone
arrow in patients with ISPT was not signiﬁcantly
ncreased (as often is seen in patients with ITP)
ompared to bone marrow biopsies in control pa-
ients (Table 2). Of note, severe hemorrhage was
are in the autotransplant population at our institu-
ion, and was listed as a cause of death in only a
ingle patient (non-ISPT group) in this study. We
nalyzed the number of platelet transfusions be-
ween patients with ISPT and patients without
SPT as a surrogate for nonlethal severe hemor-
hage. There was no difference comparing the
roup of patients without ISPT to the group of
atients with ISPT with respect to the mean (2.9
ersus 3 transfusions, respectively) or the median
umber of platelet transfusions (2 in each group).
he increment in the blood platelet count 1 hour
ollowing transfusion was not signiﬁcantly different
etween patients in the ISPT group (an increase of
4,000 platelet/L) compared to controls (an in-
rease of 29,000 platelet/L; Table 2).
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Posttransplant thrombopoiesis and autologous HPCT 899SPT Was Significantly Associated with
osttransplant Survival
The median survival for the entire population was
.2 years. Survival varied across diagnoses (P  .03),
ith median survivals for patients with acute myelo-
enous leukemia (AML) (N  18) of 1.3 years, breast
ancer (N  34) of 6.2 years, Hodgkin’s lymphoma (N 
9) of 6 years (median not reached), multiple my-
loma (N  164) of 5.5 years, non-Hodgkin’s lym-
homa (N  80) of 6 years (median not reached),
nd other diagnoses (N  4) (median not reached).
eath was documented as having occurred in 100
28%) of the 359 subjects in the study set at a median
f 1.3 years posttransplant. Of the 78 patients with a
ocumented cause of death, 69 (88%) died from their
rimary disease, 4 died from organ failure (5%), 3 died
f infection (4%), and 1 each died of graft failure (1%)
r hemorrhage (1%). We performed univariate Cox
egression analyses to identify the clinical factors as-
ociated with posttransplant survival. Because of the
ery signiﬁcant effect of diagnosis on survival (vide
upra), these analyses were stratiﬁed by disease diag-
able 3. Univariate Hazard Ratios for Death Posttransplant
ge
ex
nvolved field radiation pretransplant
ituxan pretransplant
umber of prior regimens
obilization/harvest regimens (3 categoric variables)
umber of aphereses
isease status at transplant
onditioning regimens (categoric variables)
D34 cells per kg (3 strata)
D34 CD38 cells per kg (3 strata)
ay of ANC(500) engraftment
ay of PLT(50) engraftment
osttransplant platelet >150,000/L
ases of ISPT
2 platelet transfusions
ox regression analyses were performed after stratiﬁcation by diag
able 2. Comparison of Megakarocytes in Bone Marrow Biopsies and R
id Not Develop ISPT (Controls)
Cases
ay 35 BM cellularity 36% (26 p
ay 35 megakaryocyte content in BM (25 p
Increased 16
Normal 40
Decreased 44
osttransfusion platelet increment 34,000/L (7
one marrow (BM) biopsies were performed at a median of day 3
respectively. The incremental change in the blood platelet coun
SPT indicates idiopathic secondary posttransplant thrombocytopeSPT indicates idiopathic secondary posttransplant thrombocytopenia; HRosis. The status of the patients’ primary malignancy
t the time of transplant (complete remission [CR];
artial remission [PR]; or refractory), the number of
rior chemotherapy regimens, the receipt of more
han 2 platelet transfusions posttransplant, the failure
o achieve a normal platelet count (150,000/L) in
he initial 100 days posttransplant, and the occurrence
f ISPT were signiﬁcantly associated with worse post-
ransplant survival (Table 3). These covariates were
hen entered into a multivariable model of overall
urvival (OS), stratiﬁed by disease diagnosis. Four fac-
ors were independently associated with worse sur-
ival: the number of prior regimens, the disease status
t the time of transplant, the failure to achieve a
latelet count of150,000/L in the initial posttrans-
lant engraftment period, and the occurrence of ISPT
Table 4). When the multivariate analysis was re-
eated without stratiﬁcation on diagnosis, the failure
o achieve a normal platelet count posttransplant, the
ccurrence of ISPT, and the disease status at the time
f transplant remained independently associated with
urvival (Table 4).
95% CI
P-valueLower Upper
5 0.986 1.026 NS
8 0.676 1.687 NS
2 0.813 6.022 NS
4 0.000 29.636 NS
2 1.054 2.227 .025
NS
5 0.838 1.430 NS
1.4 3.0 <.001
NS
9 0.666 1.108 NS
9 0.719 1.173 NS
5 0.934 1.082 NS
2 0.998 1.026 NS
3 0.281 0.666 <.001
8 1.034 2.723 .036
7 1.011 2.246 .044
values .05 are shown.
to Platelet Transfusions between Cases with ISPT and Patients Who
Controls No ISPT P-value
) 37% (15 patients) NS
) (16 patients) NS
0%
56%
44%
nts) 29,000/L (8 patients) NS
rols) or day 35 (ISPT) posttransplant in 6% and 42% of patients,
easured 1 hour posttransfusion.HR
1.00
1.06
2.21
0.04
1.53
1.09
2.1
0.85
0.91
1.00
1.01
0.43
1.67
1.50
nosis. Pesponse
ISPT
atients
atients
%
%
%
patie
4 (cont
t was m, hazard ratio; CI, conﬁdence interval.
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M. J. Ninan et al.900evelopment of a Thrombopoiesis Score for
osttransplant Survival
Figure 2 illustrates the effect on OS of the 3
ovariates that were most signiﬁcantly associated with
urvival in the multivariate model: the disease status at
he time of transplant, the maximal platelet count
easured during the initial engraftment period, and
able 4. Multivariable Model with Hazard Ratios for Death Post-Tra
aximal initial posttransplant platelet count <150,000/L*
SPT*
umber of prior regimens
isease status at transplant*
actors that were signiﬁcant in univariate analyses (Table 3, P .05
disease diagnosis.
I indicates conﬁdence interval; HR, hazard ratio; IPST, isiopathi
Three factors, a subnormal maximal platelet count posttransplant, I
survival in a multivariate model in which the analysis was not stra
and 1.8 (1.3-2.4) respectively.
igure 2. Kaplan-Meier estimates of overall survival of patients s
urvival curves are shown for patients stratiﬁed by A, remission sta
osttransplant platelet count of at least 150,000/L and C, the pres
ntire group of patients is stratiﬁed into 3 groups by the thrombop
oint each for the presence of a posttransplant platelet count of 
easurements on 359 patients except for panel A (358 patients; 1
xcluded from the analysis).he presence of ISPT. Patients in PR or with refrac-
ory cancer at the time of transplant had worse survival
han patients in CR (P  .001; Figure 2A). Patients
ho never achieved a platelet count of 150,000/L
t the time of initial engraftment had signiﬁcantly
orse OS than patients who achieved initial platelet
ounts 150,000 posttransplant (P  .0001), and pa-
Stratiﬁed by Disease Diagnosis
HR
95% CI
P-valueLower Upper
2.3 1.5 3.5 <.001
2.1 1.3 3.5 .003
1.4 1.1 2.0 .022
2.0 1.4 2.9 <.001
included in a forward conditional multivariate model, stratiﬁed by
dary posttransplant thrombocytopenia.
nd disease status at transplant were also signiﬁcantly associated with
y disease diagnosis with HR (95%CI) of 2.3 (1.5-3.4), 1.9 (1.2-2.9),
by covariates associated with survival in the multivariate model.
heir malignancy at the time of transplant, B, the achievement of a
ISPT. P values based on log-rank comparisons are shown. D, The
core, combining the effects seen in panels B and C by assigning 1
0/L and the occurrence of ISPT. All graphs represent outcome
with amyloidosis who was conditioned without prior therapy wasnsplant,
) were
c secon
SPT, a
tiﬁed btratiﬁed
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Posttransplant thrombopoiesis and autologous HPCT 901ients with ISPT had signiﬁcantly worse survival than
atients without ISPT (P  .008) (Figure 2B and C,
espectively). Two covariates related to posttransplant
hrombopoiesis in the multivariable analysis, namely,
he failure to achieve a platelet count of 150,000 in
he ﬁrst 100 days posttransplant and the presence of
SPT, were used to generate a prognostic score (the
thrombopoiesis score”), in which 1 point was as-
igned for the presence of either factor, for a total
core of 0, 1, or 2. One hundred eighty-nine patients
ad a prognostic score of 0 and have not reached a
edian survival; 145 patients had a score of 1 and have
median survival of 4.3 years; and 25 patients had a
core of 2 and have a median survival of 1.7 years (P
001 by log rank comparison; Figure 2D). The com-
ination of low platelet counts at the time of initial
ngraftment and ISPT was associated with a very poor
ong-term survival, with an estimated 5-year survival
f 15% for this subset (Figure 2D). Eighty-two
ercent of the deaths observed in the group with both
ow platelet counts and ISPT (in which a cause of
eath was recorded) resulted from the patients’ pri-
ary disease. Application of this prognostic score to
ach of the different disease categories represented in
he study set showed that the score was signiﬁcantly
ssociated with OS among patients in the 2 categories
ith the largest numbers of patients: multiple my-
loma (N  164, P  .0001), and non-Hodgkin’s
ymphoma (N  80, P  .01).
ignificance of the Thrombopoiesis Score on OS
fter Stratification on Disease Status at the Time
f Transplant
To address the question of the relationship of
igure 3. Kaplan-Meier estimates of overall survival of patients st
hown for patients according to their remission status of their mal
ransplanted in CR; B, 205 patients transplanted in PR; C, 30 pat
hrombopoiesis score with P-values based on log-rank compariso
myloidosis who was conditioned without prior therapy.osttransplant thrombopoiesis with disease status, we aepeated the multivariate analysis stratifying on remis-
ion status at the time of transplant. The occurrence of
SPT (P .002), the failure to achieve a platelet count
f 150,000 (P  .001), the number of prior chemo-
herapy regimens (P  .019), and the diagnosis (P 
01) were signiﬁcant covariates associated with death.
e analyzed the signiﬁcance of the “thrombopoiesis
core” on the entire population stratiﬁed by their
retransplant remission status and present these data
raphically in Figure 3. As expected, the 123 patients
ho were in CR1 or CR2 at the time of transplant had
he best OS, and although the thrombopoiesis score
eparated the survival curves of this group, the differ-
nces were not signiﬁcant by log-rank test (P  .12).
mong the large group of 205 patients transplanted
ith chemosensitive disease in PR, the thrombopoie-
is score produced a very signiﬁcant stratiﬁcation in
urvival (P .0001). Among the smaller number of 30
atients transplanted with refractory disease (mostly
atients with refractory Hodgkin’s lymphoma or mul-
iple myeloma) the thrombopoiesis score again sepa-
ated these populations into groups with statistically
ifferent survival experiences posttransplant (P 
0001).
ssociation of the Covariates in the Multivariate
odel with Engraftment Kinetics and Numbers of
ransplanted Progenitor Cells
We compared the mean values for days to granu-
ocyte and platelet engraftment and the numbers of
ransplanted CD34 and CD34 CD38 cells across
ach of the covariates in the multivariate model to test
1) whether these clinical factors (including ISPT and
ow initial platelet counts) were signiﬁcantly associ-
by remission status at the time of transplant. Survival curves are
at the time of transplant. A, One hundred twenty-three patients
ansplanted with refractory disease. Each group is stratiﬁed by the
n. Outcome data on 358 patients exclude the one patient withratiﬁed
ignancy
ients tr
ns showted with the kinetics of engraftment, and (2) whether
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M. J. Ninan et al.902hey were associated with transplantation of fewer
ematopoietic progenitor cells. Platelet and granulo-
yte engraftment kinetics did not vary signiﬁcantly be-
ween patients who received 1, 2, 3, or 4 prior regimens
data not shown), but did vary according to the content
f CD34 cells in the graft. More rapid engraftment
ccurred among the third of patients receiving the high-
st number of CD34 cells/kg achieved platelet count
50,000/L) at a median of 17 days compared to 18 days
mong the third of patients receiving the lowest number
f CD34 cells/kg (P  .0001). Patients who failed to
chieve a posttransplant platelet count of 150,000/L
eceived signiﬁcantly fewer numbers of transplanted
D34 cells/kg (P  .0001, Table 5), whereas patients
ith ISPT received equivalent numbers of total CD34
ells but fewer CD34CD38 cells/kg (0.076  10E6/
g) than patients who did not develop ISPT (0.13 10E6/
g, P  .001, Table 5).
ISCUSSION
This is the largest single-institution retrospective
tudy on the kinetics of platelet engraftment following
utologous HPCT that we are aware of, and provides
ome interesting observations. First, the phenomenon
f ISPT appears relatively common, occurring in 17%
f patients. Second, although most patients recovered
rom secondary thrombocytopenia, the subset of pa-
ients who never achieved a normal platelet count
osttransplant and then had a secondary decline in
latelet counts following initial engraftment had a
ery poor long-term outcome, with most deaths from
elapse of their primary disease (Figure 2). A lower
able 5. Risk Factors for Posttransplant Death in the Multivariable M
f Total CD34 Cells and CD34 CD38 Cells in the Hematopoietic G
Days to ANC >500/L
Days to
>50,0
Mean SEM P-value Mean SEM
SPT
Present (62) 12.7 0.2 NS 18.4 0.7
Absent (297) 13.4 0.2 21.1 0.7
aximal platelets
<150 K/L (133) 13.3 0.3 NS 26.5 1.3
>150 K/L (226) 13.2 0.2 17.2 0.5
tatus at transplant
CR (123) 13.0 0.2 NS 20.9 1.0
PR (205) 13.4 0.2 20.6 0.8
REF (30) 13.2 0.8 20.5 1.7
rior regimens
<1 (186) 13.4 0.2 NS 20.6 0.8
ean values with standard error of the mean (SEM) for the numbe
the content (per kg) of CD34 and CD34CD38 cells in the gr
covariates identiﬁed in the in multivariable model (ISPT and fa
cut point greater than the median number of prior regimens (me
t-test. Nonequal variances were used.
NC indicates absolute neutrophil count; CR, complete remissionlatelet count at the time of initial engraftment was ossociated with transplantation of fewer numbers of
otal CD34 cells, whereas the occurrence of ISPT
as associated with transplantation of fewer CD34
D38 cells. These data suggest that both the quan-
ity and quality of autologous hematopoietic progen-
tor cells in the graft are important prognostic vari-
bles for long-term survival, in addition to being
arkers for initial hematopoietic engraftment.
One question raised by this analysis is why post-
ransplant thrombopoiesis is associated with long-
erm survival in this group of patients. Because we
imited the analysis to patients who had engrafted with
latelet counts of 50,000/L, the association of
easures of posttransplant thrombopoiesis with sur-
ival is not because of death from graft failure or very
arly regimen-related toxicities. We think that the
hrombopoiesis score is a surrogate for the activity of
he underlying malignancy in patients following high-
ose chemotherapy and autologous HPCT. In this
etrospective review of 359 patients, the schedule for
osttransplant restaging varied according to the diag-
osis, and occurred at various times between day 30
nd 6 months posttransplant. Although controlling for
he remission status achieved posttransplant in our
nalysis was not practical, the disease status at the time
f transplant provides an indication as to the chemo-
ensitivity of the underlying malignancy. The occur-
ence of ISPT and the maximal platelet count
chieved in the initial period of engraftment post-
ransplant were combined into a thrombopoiesis score
hat signiﬁcantly associated with posttransplant OS of
ll patients (Figure 2D), and most signiﬁcantly asso-
iated with survival among patients transplanted in PR
ere Associated with Delayed Platelet Engraftment and Lower Numbers
t
CD34 (x10E6)/kg
CD34 CD38 (x10E6)/
kg
value Mean SEM P-value Mean SEM P-value
NS 8.8 0.9 NS 0.076 0.010 .0006*
10.3 0.8 0.134 0.014
.0001 7.3 0.7 <.0001* 0.142 0.024 NS
11.7 0.9 0.113 0.011
NS 10.1 1.3 NS 0.130 0.021 NS
9.6 0.6 0.116 0.012
12.9 3.6 0.150 0.064
NS 9.9 0.7 NS 0.102 0.01 .05
ys to achieve myelogenous engraftment, platelet engraftment, and
calculated. Patients were stratiﬁed into groups by the dichotomous
achieve a normal platelet count post-transplant) or according to a
1). Statistical comparison between means was performed using the
artial remission.odel W
raft
Platele
00/L
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<
r of da
aft were
ilure to
dian ofr with refractory cancer (Figure 3). Thus, the asso-
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Posttransplant thrombopoiesis and autologous HPCT 903iation of the thrombopoiesis score with survival
mong patients beginning conditioning with evidence
f residual disease (PR or refractory groups), and the
act that 88% of posttransplant deaths were from
isease progression suggests that impaired posten-
raftment thrombopoiesis reﬂects failure of the high-
ose chemotherapy to eradicate residual disease in the
atient. Because ISPT and lower platelet counts dur-
ng initial engraftment were both independent covari-
tes with OS in a multivariate model (Table 4), the
hrombopoiesis score is not simply a surrogate for the
xtent of prior therapy. One speculative hypothesis is
hat tumor stem cells and normal hematopoietic stem
ells compete for the same niches in hematopoietic
icroenvironments. As markers for tumor stem cells
ecome more reﬁned, this may be a testable hypoth-
sis if accessible sites, such as the bone marrow, could
e sampled at various time points before and after
tem cell transplantation.
There was a signiﬁcant association between the fail-
re to achieve an initial platelet count of 150,000/L
ith a lower dose of total CD34 cells in the graft, as
ell as an association of ISPT with grafts containing
ewer CD34 CD38 cells (Table 5). The minimum
uantity of CD34 cells required for consistent en-
raftment is unknown, but is probably between 1-2 
0E6 cells/kg [3,21] and predicts the kinetics for en-
raftment of granulocyte and platelets following au-
ologous transplantation [5,22,23]. As expected, we
bserved slower rates for initial platelet engraftment
mong those patients who received fewer CD34 cells
n their graft. Because the study set was limited to
atients who achieved initial platelet engraftment, the
ssociation of a lower CD34 cell dose with the ki-
etics of platelet engraftment was not from the inclu-
ion of patients who failed to engraft. Of note, patients
ith ISPT had a shorter time to reach a transfusion-
ndependent platelet count of 50,000/L (Table 5),
ndicating that ISPT was not primarily associated with
he kinetics of the initial engraftment.
Subsets of CD34 cells have been reported to
redict the kinetics of early platelet engraftment [24].
ur study also conﬁrmed a modest effect of the dose
f CD34 CD38 cells on early platelet engraftment,
lthough the effect of the total CD34 cell dose was
ore signiﬁcant in a multivariate model (data not
hown). The phenomena of ISPT may be related to
atients receiving a smaller number of long-term re-
opulating stem cells that are contained in the CD34
D38 subpopulation. In murine and sheep models,
nly recipients transplanted with CD34 CD38 cells
but not those with CD34 CD38 cells) have been
hown to exhibit long-term engraftment during serial
ransplantations [20], and the CD34 CD38 subset
ay represent the long-term repopulating cells re-
ponsible for sustained engraftment [25]. Although
he optimum number of CD34 CD38 cells in theraft to achieve rapid and durable hematopoietic re-
onstitution has been deﬁned as 5  104 cells/kg
ody weight [13,26,27], our analyses indicate that
igher numbers are insufﬁcient, in some cases, for
table engraftment. A possible explanation for the as-
ociation of fewer numbers of CD34 CD38 cells
ith the occurrence of ISPT and the association of
otal CD34 cells with the maximal platelet count
easured during the initial engraftment period is
rom the presence of long-term repopulating stem
ells in the former population, and the presence of
ommitted progenitors in the later population. Alter-
atively, the CD34 CD38 subset of the hemato-
oietic graft could contain stromal progenitors [28]
hat may be important in facilitating thrombopoiesis
n the marrow microenvironment [29].
We did not ﬁnd a direct association between the
uantity of CD34 or CD34CD38 cells trans-
lanted and survival in this study (Table 2). These
ndings are in contrast to studies of allogeneic trans-
lantation, in which greater numbers of CD34 cells
n a marrow (but not blood HPC) graft are associated
ith improved survival [30,31]. Thus, measurements
f the number of CD34 cells or CD34 CD38 cells
n the autologous HPC graft are an imperfect assess-
ent of stem cell quality and do not fully predict
ematopoiesis.
Finally, we did not demonstrate an autoimmune
tiology for ISPT observed in patients undergoing
utologous HPCT. We found equivalent numbers of
one marrow megakaryocytes in day 35 marrow
amples from patients with ISPT compared to bone
arrow biopsies from patients without ISPT
Table 3); equivalent posttransfusion increments in
lood platelet counts comparing the 2 groups (Table
); and a lack of therapeutic response of blood platelet
ount to trials of immunosuppressive therapies that
ncluded an average of more than 40 mg prednisone/
ay for a month in a subset of ISPT patients (Figure
C). We suggest avoidance of immunosuppressive
rug therapy in patients who do not have evidence for
PT.
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